Shamaa Marium M
Clinical and Biological Sciences Division, Biochemistry Department, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt.
Biochem Genet. 2025 May 27. doi: 10.1007/s10528-025-11141-z.
Hepatocellular carcinoma (HCC), the most common liver cancer, has limited treatment options. The author investigated novel combinations of regorafenib (Reg) with diosmin (Dio), sulfasalazine (SZZ), or rosuvastatin (Ros) to enhance anti-HCC efficacy. Each agent potentiated Reg activity via distinct pathway modulation: Reg/Dio inhibited Akt/m-TOR and RAF/ERK; Reg/SZZ suppressed Akt/m-TOR and NF-κB; and Reg/Ros suppressed JAK/STAT3 and RAF/ERK. These findings demonstrate synergistic potential by combining Reg with drugs possessing complementary anti-inflammatory, cholesterol-lowering, or cytotoxic activities, offering promising multi-targeted therapeutic strategies for HCC.
肝细胞癌（HCC）是最常见的肝癌，其治疗选择有限。作者研究了瑞戈非尼（Reg）与地奥司明（Dio）、柳氮磺胺吡啶（SZZ）或瑞舒伐他汀（Ros）的新型联合用药，以增强抗肝癌疗效。每种药物都通过不同的途径调节来增强Reg的活性：Reg/Dio抑制Akt/m-TOR和RAF/ERK；Reg/SZZ抑制Akt/m-TOR和NF-κB；Reg/Ros抑制JAK/STAT3和RAF/ERK。这些发现表明，将Reg与具有互补抗炎、降胆固醇或细胞毒性活性的药物联合使用具有协同潜力，为HCC提供了有前景的多靶点治疗策略。
